Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2022 | Optimal management of MGCS-related disorders

Nelson Leung • 25 Aug 2022
IMS 2022
Multiple Myeloma Rare Diseases Smoldering Myeloma Anakinra Rituximab

Nelson Leung, Mayo Clinic, Rochester, MN, comments on the management of monoclonal gammopathy of clinical significance (MGCS)-related disorders including monoclonal gammopathy-related keratopathy, monoclonal gammopathy of renal significance, Schnitzler syndrome, and scleromyxedema. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Nelson Leung

0:59
Current approaches to treating and managing MGUS
Nelson Leung • 28 Sep 2023
1:51
Diagnosis and potential therapeutic options for AA amyloidosis
Nelson Leung • 28 Sep 2023
1:22
Addressing nephrotoxicity in agents commonly used to treat multiple myeloma
Nelson Leung • 28 Sep 2023
0:58
Understanding the concept of MGRS
Nelson Leung • 28 Sep 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals